FLT3 and acute myeloid leukemia: The MOLM-13 and the MV4-11 lines have been used in many studies leading to the discovery of selective FLT3 inhibitors [175,176,177], e.g., the LT-171-861 recently discovered and selected for clinical trials in AML patients with FLT3-ITD mutations [178].